Open access · CC-BY
via OpenAlex
Application of the Yamanaka Transcription Factors Oct4, Sox2, Klf4, and c-Myc from the Laboratory to the Clinic
Marisol Aguirre, Manuela Escobar, Sebastián Forero Amézquita, David Cubillos, Camilo Andrés Rincón Romero, Paula Vanegas, María Paula Tarazona, S Escobar, Juan Camilo Blanco, Luís Gustavo Celis
Genes · 2023 · ▲ 52 citations
Abstract
The transcription factors Oct4, Sox2, Klf4, and c-Myc enable the reprogramming of somatic cells into induced pluripotent cells. Reprogramming generates newly differentiated cells for potential therapies in cancer, neurodegenerative diseases, and rejuvenation processes. In cancer therapies, these transcription factors lead to a reduction in the size and aggressiveness of certain tumors, such as sarcomas, and in neurodegenerative diseases, they enable the production of dopaminergic cells in Parkinson’s disease, the replacement of affected neuronal cells in olivopontocerebellar atrophy, and the regeneration of the optic nerve. However, there are limitations, such as an increased risk of cancer development when using Klf4 and c-Myc and the occurrence of abnormal dyskinesias in the medium term, possibly generated by the uncontrolled growth of differentiated dopaminergic cells and the impairment of the survival of the new cells. Therefore, the Yamanaka transcription factors have shown therapeutic potential through cell reprogramming for some carcinomas, neurodegenerative diseases, and rejuvenation. However, the limitations found in the studies require further investigation before the use of these transcription factors in humans.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/genes14091697
- Canonical
- link ↗
- Fetched
- 2026-10-31 MST
Cite this
APA
Aguirre, M., Escobar, M., Amézquita, S.F., Cubillos, D., Romero, C.A.R., Vanegas, P., Tarazona, M.P., Escobar, S., Blanco, J.C., & Celis, L.G. (2023). Application of the Yamanaka Transcription Factors Oct4, Sox2, Klf4, and c-Myc from the Laboratory to the Clinic. <em>Genes</em>. https://doi.org/10.3390/genes14091697
Vancouver
Aguirre M, Escobar M, Amézquita SF, Cubillos D, Romero CAR, Vanegas P, et al. Application of the Yamanaka Transcription Factors Oct4, Sox2, Klf4, and c-Myc from the Laboratory to the Clinic. Genes. 2023. doi:10.3390/genes14091697.
BibTeX
@article{marisol2023Applic,
title = {Application of the Yamanaka Transcription Factors Oct4, Sox2, Klf4, and c-Myc from the Laboratory to the Clinic},
author = {Marisol Aguirre and Manuela Escobar and Sebastián Forero Amézquita and David Cubillos and Camilo Andrés Rincón Romero and Paula Vanegas and María Paula Tarazona and S Escobar and Juan Camilo Blanco and Luís Gustavo Celis},
journal = {Genes},
year = {2023},
doi = {10.3390/genes14091697},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Progress in Neurobiology 2022
Open access · CC-BY
Reprogramming neurons for regeneration: The fountain of youth
Frontiers in Cellular Neuroscience 2018
Open access · CC-BY
Potentials of Cellular Reprogramming as a Novel Strategy for Neuroregeneration
MedComm 2023
Open access · CC-BY
Metabolic reprogramming in cancer: Mechanisms and therapeutics
Pharmaceutics 2022
Open access · CC-BY
Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches
Biochemistry 2023
Open access · CC-BY
Induced Pluripotent Stem Cells: Advances and Applications in Regenerative Medicine
Frontiers in Cell and Developmental Biology 2021
Open access · CC-BY